Latest news and press releases about Adicet Bio, Inc. (ACET): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies.
Price
| Price | $9.05 |
| Market Cap | $85M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.82 |
| EV / EBITDA | -0.77 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -74.90% |
| Return on Invested Capital | -77.98% |
| Return on Assets | -66.80% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACRV · ADAG · CRVO · GANX · HOWL · IMUX · IOBT
Explore sector: Healthcare · Biotechnology
More sections of ACET: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks